Cargando…

Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea

PURPOSE: M1 macrophages can promote corneal allograft rejection (CGR). Inhibiting M1 macrophage polarization by the JAK/STAT1 pathway may be a new strategy to prevent CGR. Tofacitinib, a potent pan-JAK inhibitor, can inhibit JAK/STAT activation. Here, we investigated the inhibitory effects of tofaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jianfeng, Li, Pengfei, Li, Zhuang, Li, Yingqi, Luo, Jiawei, Su, Wenru, Liang, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976928/
https://www.ncbi.nlm.nih.gov/pubmed/35353151
http://dx.doi.org/10.1167/tvst.11.3.34
_version_ 1784680669117415424
author Yu, Jianfeng
Li, Pengfei
Li, Zhuang
Li, Yingqi
Luo, Jiawei
Su, Wenru
Liang, Dan
author_facet Yu, Jianfeng
Li, Pengfei
Li, Zhuang
Li, Yingqi
Luo, Jiawei
Su, Wenru
Liang, Dan
author_sort Yu, Jianfeng
collection PubMed
description PURPOSE: M1 macrophages can promote corneal allograft rejection (CGR). Inhibiting M1 macrophage polarization by the JAK/STAT1 pathway may be a new strategy to prevent CGR. Tofacitinib, a potent pan-JAK inhibitor, can inhibit JAK/STAT activation. Here, we investigated the inhibitory effects of tofacitinib on M1 macrophage polarization and its therapeutic effect on rat CGR. METHODS: Corneal allograft transplantation was performed and administrated with 0.3% tofacitinib in rats. The corneal allografts were assessed clinically. The corneas were detected for M1 macrophages, lymphatic vessels, and inflammatory cytokine expression using immunohistochemistry and real-time polymerase chain reaction (PCR). Dendritic cells (DCs) in ipsilateral cervical lymph nodes were detected by flow cytometry. The effect and mechanism of tofacitinib on macrophages were explored by real-time PCR, enzyme-linked immunoassay, and western blot analysis in vitro. RESULTS: The results showed that topical administration of 0.3% tofacitinib significantly prolonged corneal graft survival. Tofacitinib-treated corneal allografts displayed a proportionate decrease in M1 macrophages and reduced lymphatic vessel density with fewer DCs in rat ipsilateral cervical lymph nodes. Tofacitinib reduced the mRNA expression of inflammatory cytokines, including iNOS, MCP-1, TNF-α, IL-6, IL-1β, and VEGF-C, and inhibited STAT1 activation in rat corneal grafts. In addition, tofacitinib suppressed M1 macrophage polarization via STAT1 activation after IFN-γ and lipopolysaccharide stimulation in vitro. CONCLUSIONS: Tofacitinib could suppress M1 macrophage polarization and subsequently delay CGR by inhibiting STAT1 activation. The data indicate that tofacitinib is an effective drug for CGR. TRANSLATIONAL RELEVANCE: This study provided evidence that topical administration of 0.3% tofacitinib may be a novel clinical strategy to prevent CGR.
format Online
Article
Text
id pubmed-8976928
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Association for Research in Vision and Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-89769282022-04-04 Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea Yu, Jianfeng Li, Pengfei Li, Zhuang Li, Yingqi Luo, Jiawei Su, Wenru Liang, Dan Transl Vis Sci Technol Article PURPOSE: M1 macrophages can promote corneal allograft rejection (CGR). Inhibiting M1 macrophage polarization by the JAK/STAT1 pathway may be a new strategy to prevent CGR. Tofacitinib, a potent pan-JAK inhibitor, can inhibit JAK/STAT activation. Here, we investigated the inhibitory effects of tofacitinib on M1 macrophage polarization and its therapeutic effect on rat CGR. METHODS: Corneal allograft transplantation was performed and administrated with 0.3% tofacitinib in rats. The corneal allografts were assessed clinically. The corneas were detected for M1 macrophages, lymphatic vessels, and inflammatory cytokine expression using immunohistochemistry and real-time polymerase chain reaction (PCR). Dendritic cells (DCs) in ipsilateral cervical lymph nodes were detected by flow cytometry. The effect and mechanism of tofacitinib on macrophages were explored by real-time PCR, enzyme-linked immunoassay, and western blot analysis in vitro. RESULTS: The results showed that topical administration of 0.3% tofacitinib significantly prolonged corneal graft survival. Tofacitinib-treated corneal allografts displayed a proportionate decrease in M1 macrophages and reduced lymphatic vessel density with fewer DCs in rat ipsilateral cervical lymph nodes. Tofacitinib reduced the mRNA expression of inflammatory cytokines, including iNOS, MCP-1, TNF-α, IL-6, IL-1β, and VEGF-C, and inhibited STAT1 activation in rat corneal grafts. In addition, tofacitinib suppressed M1 macrophage polarization via STAT1 activation after IFN-γ and lipopolysaccharide stimulation in vitro. CONCLUSIONS: Tofacitinib could suppress M1 macrophage polarization and subsequently delay CGR by inhibiting STAT1 activation. The data indicate that tofacitinib is an effective drug for CGR. TRANSLATIONAL RELEVANCE: This study provided evidence that topical administration of 0.3% tofacitinib may be a novel clinical strategy to prevent CGR. The Association for Research in Vision and Ophthalmology 2022-03-30 /pmc/articles/PMC8976928/ /pubmed/35353151 http://dx.doi.org/10.1167/tvst.11.3.34 Text en Copyright 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Article
Yu, Jianfeng
Li, Pengfei
Li, Zhuang
Li, Yingqi
Luo, Jiawei
Su, Wenru
Liang, Dan
Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea
title Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea
title_full Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea
title_fullStr Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea
title_full_unstemmed Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea
title_short Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea
title_sort topical administration of 0.3% tofacitinib suppresses m1 macrophage polarization and allograft corneal rejection by blocking stat1 activation in the rat cornea
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976928/
https://www.ncbi.nlm.nih.gov/pubmed/35353151
http://dx.doi.org/10.1167/tvst.11.3.34
work_keys_str_mv AT yujianfeng topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea
AT lipengfei topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea
AT lizhuang topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea
AT liyingqi topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea
AT luojiawei topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea
AT suwenru topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea
AT liangdan topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea